EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

HIV‐DNA decrease during treatment in primary HIV‐1 infection with three different drug regimens: Italian Network of Acute HIV Infection (INACTION) clinical trial

Elena Bruzzesi iD, Arianna Gabrieli iD, Davide Bernasconi iD, Giulia Marchetti iD, Andrea Calcagno iD, Diego Ripamonti iD, Andrea Antinori iD, Nicola Squillace iD, Antonella Cingolani iD, Antonio Muscatello iD, Alessandra Bandera iD, Andrea Gori und 3 weitere

Journal of Medical Virology · 2023

DOI: 10.1002/jmv.29114 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Medical Virology, 2023. Verfasst von Elena Bruzzesi und 14 weiteren Autor:innen. Beteiligte Einrichtung: Vita-Salute San Raffaele University, Milan, Italy. Hauptthemen laut MEDLINE: Anti-HIV Agents, HIV Infections, HIV-1. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As the introduction of antiretroviral therapy (ART) during primary HIV‐1 infection (PHI) could restrict the establishment of HIV reservoirs, we aimed to assess the effect of three different ART regimens on HIV‐DNA load in people living with HIV (PLWH), who started ART in PHI. Randomized, open‐label, multicentric study, including subjects in PHI (defined as an incomplete HIV‐1 Western blot and detectable plasma HIV‐RNA) in the Italian Network of Acute HIV Infection cohort. Participants were randomly assigned (10:10:8) to a fixed‐dose combination of tenofovir alafenamide fumarate (TAF) 10 mg plus emtricitabine (FTC) 200 mg, darunavir 800 mg, and cobicistat 150 mg once daily (group A), or TAF 25 mg plus FTC 200 mg, dolutegravir 50 mg once daily (group B), or an intensified four‐drug regimen (TAF 10 mg plus FTC 200 mg, dolutegravir 50 mg, darunavir 800 mg, and cobicistat 150 mg once daily) (group C). The primary endpoint was the decrease of HIV‐DNA copies/10 6 peripheral blood mononuclear cells (PBMCs) at weeks (W) 12 and 48. Secondary endpoints were increased in CD4+ cells and in CD4+/CD8+ ratio and percentage of PLWH reaching undetectable HIV‐RNA. HIV‐DNA was quantified by Droplet Digital PCR (Biorad QX100) and normalized to RPP30 reference gene. This study was registered in ClinicalTrials.gov (number NCT04225325). Among 78 participants enrolled, 30 were randomized to group 1, 28 to group 2, and 20 to group 3. At baseline, median CD4+ count was 658/µL (476–790), HIV‐RNA 5.37 (4.38, 6.12) log 10 copies/mL, without statistical difference in their change among groups at weeks 12 and 48 ( p = 0.432 and 0.234, respectively). The trial was prematurely discontinued for slow accrual and for COVID‐19 pandemic‐associated restrictions. In the per‐protocol analysis, PLWH ( n = 72) with undetectable viral load was 54.3% at W12 and 86.4% at W48. Interestingly, the CD4/CD8 ratio progressively increased over time, up to normalization in almost half of the cohort by week 48, despite a deflection in group 3; no difference was observed by the Fiebig stage (I–III vs. IV–VI). HIV‐DNA decreased from 4.46 (4.08, 4.81) log 10 copies/10 6 PBMCs to 4.22 (3.79, 4.49) at week 12, and 3.87 (3.46, 4.34) at week 48, without difference among groups. At multivariable analysis, HIV‐DNA delta at W48 was associated only with the increase of CD4+ count by 100 cells/mm 3 but not with the Fiebig stage, the CD4+/CD8+ ratio, and treatment arm, despite a higher decrease in group 3. Six adverse events were recorded during our study, which did not cause any withdrawal from the study. We observed a decrease in HIV‐DNA from baseline to W48 in PLWH treated during PHI, associated with an increase in CD4+ count, unrelated to the treatment arm.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-HIV AgentsHIV InfectionsHIV-1HumansCobicistatDarunavirEmtricitabineLeukocytes, MononuclearRNATenofovirViral Load

Stichwörter der Autor:innen

HIVHIV-DNAantiretroviral therapyprimary HIV infection

Substanzen

Anti-HIV AgentsCobicistatDarunavirEmtricitabineRNATenofovir

Autor:innen und Institutionen

  • Vita-Salute San Raffaele University, Milan, Italy.
  • Dipartimento di Scienze Biomediche e Cliniche (DIBIC), Milan, Italy.
  • Bicocca Bioinformatics Biostatistics and Bioimaging Centre - B4 School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
  • Clinic of Infectious Diseases, Department of Health Sciences, ASST Santi Paolo e Carlo, University of Milan, Milan, Italy.
  • School of Medicine and Surgery, University of Milan, Milan, Italy.
  • Unit of Infectious Diseases, Department of Medical Sciences, University of Turin, Turin, Italy.

ORCID-Profile: Elena Bruzzesi, Arianna Gabrieli, Davide Bernasconi, Giulia Marchetti, Andrea Calcagno, Diego Ripamonti, Andrea Antinori, Nicola Squillace, Antonella Cingolani, Antonio Muscatello, Alessandra Bandera, Stefano Rusconi, Silvia Nozza

Zitieren

APA

Bruzzesi, E., Gabrieli, A., Bernasconi, D., Marchetti, G., Calcagno, A., Ripamonti, D., Antinori, A., Squillace, N., Cingolani, A., Muscatello, A., Bandera, A., Gori, A., Rusconi, S., Nozza, S., & INACTION Study Group (2023). HIV‐DNA decrease during treatment in primary HIV‐1 infection with three different drug regimens: Italian Network of Acute HIV Infection (INACTION) clinical trial. Journal of Medical Virology. https://doi.org/10.1002/jmv.29114

Vancouver

Bruzzesi E, Gabrieli A, Bernasconi D, Marchetti G, Calcagno A, Ripamonti D, et al. HIV‐DNA decrease during treatment in primary HIV‐1 infection with three different drug regimens: Italian Network of Acute HIV Infection (INACTION) clinical trial. Journal of Medical Virology. 2023. doi:10.1002/jmv.29114

BibTeX
@article{Bruzzesi2023,
  author = {Bruzzesi, Elena and Gabrieli, Arianna and Bernasconi, Davide and Marchetti, Giulia and Calcagno, Andrea and Ripamonti, Diego and Antinori, Andrea and Squillace, Nicola and Cingolani, Antonella and Muscatello, Antonio and Bandera, Alessandra and Gori, Andrea and Rusconi, Stefano and Nozza, Silvia and INACTION Study Group, INACTION Study Group},
  title = {HIV‐DNA decrease during treatment in primary HIV‐1 infection with three different drug regimens: Italian Network of Acute HIV Infection (INACTION) clinical trial},
  journal = {Journal of Medical Virology},
  year = {2023},
  doi = {10.1002/jmv.29114}
}
Kostenlos starten →